Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

被引：74
|
作者：
Cummings, J. [1 ]
Raynaud, F. [2 ]
Jones, L. [3 ]
Sugar, R. [4 ]
Dive, C. [1 ]
机构：
[1] Univ Manchester, Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England
[2] Inst Canc Res, Canc Res UK Ctr Canc Therapeut, Haddow Labs, Sutton SM2 5NG, Surrey, England
[3] Canc Res UK, Translat Res Team, Clin & Translat Operat & Funding Directorate, London WC2A 3PX, England
[4] Canc Res UK, Drug Dev Off, Clin & Translat Operat & Funding Directorate, London WC2A 3PX, England
来源：
BRITISH JOURNAL OF CANCER | 2010年 / 103卷 / 09期
关键词：
biomarkers; validation; clinical trials; fit-for-purpose; BIOANALYTICAL METHOD VALIDATION; LIGAND-BINDING ASSAYS; CELL-DEATH; CANCER; MACROMOLECULES; STABILITY; QUALITY; SAMPLES;
D O I：
10.1038/sj.bjc.6605910
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Clinical development of new anticancer drugs can be compromised by a lack of qualified biomarkers. An indispensable component to successful biomarker qualification is assay validation, which is also a regulatory requirement. In order to foster flexible yet rigorous biomarker method validation, the fit-for-purpose approach has recently been developed. This minireview focuses on many of the basic issues surrounding validation of biomarker assays utilised in clinical trials. It also provides an overview on strategies to validate each of the five categories that define the majority of biomarker assays. British Journal of Cancer (2010) 103, 1313-1317. doi: 10.1038/sj.bjc.6605910 www.bjcancer.com Published online 5 October 2010 (C) 2010 Cancer Research UK
引用
收藏
页码：1313 / 1317
页数：5
相关论文
共 50 条
  • [1] Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs
    J Cummings
    F Raynaud
    L Jones
    R Sugar
    C Dive
    British Journal of Cancer, 2010, 103 : 1313 - 1317
  • [2] Fit-for-purpose biomarker method validation in anticancer drug development
    Cummings, Jeffrey
    Ward, Tim H.
    Dive, Caroline
    DRUG DISCOVERY TODAY, 2010, 15 (19-20) : 816 - 825
  • [3] Fit-for-purpose method development and validation for successful biomarker measurement
    Lee, JW
    Devanarayan, V
    Barrett, YC
    Weiner, R
    Allinson, J
    Fountain, S
    Keller, S
    Weinryb, I
    Green, M
    Duan, L
    Rogers, JA
    Millham, R
    O'Brien, PJ
    Sailstad, J
    Khan, M
    Ray, C
    Wagner, JA
    PHARMACEUTICAL RESEARCH, 2006, 23 (02) : 312 - 328
  • [4] Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement
    Jean W. Lee
    Viswanath Devanarayan
    Yu Chen Barrett
    Russell Weiner
    John Allinson
    Scott Fountain
    Stephen Keller
    Ira Weinryb
    Marie Green
    Larry Duan
    James A. Rogers
    Robert Millham
    Peter J. O'Brien
    Jeff Sailstad
    Masood Khan
    Chad Ray
    John A. Wagner
    Pharmaceutical Research, 2006, 23 : 312 - 328
  • [5] Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
    Brookes, K.
    Cummings, J.
    Backen, A.
    Greystoke, A.
    Ward, T.
    Jayson, G. C.
    Dive, C.
    BRITISH JOURNAL OF CANCER, 2010, 102 (10) : 1524 - 1532
  • [6] Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
    K Brookes
    J Cummings
    A Backen
    A Greystoke
    T Ward
    G C Jayson
    C Dive
    British Journal of Cancer, 2010, 102 : 1524 - 1532
  • [7] "Fit-for-Purpose" Method Validation and Application of a Biomarker (C-terminal Telopeptides of Type 1 Collagen) in Denosumab Clinical Studies
    Wang, Jin
    Lee, Jean
    Burns, Daniel
    Doherty, David
    Brunner, Laura
    Peterson, Mark
    DeSilva, Binodh
    AAPS JOURNAL, 2009, 11 (02): : 385 - 394
  • [8] “Fit-for-Purpose” Method Validation and Application of a Biomarker (C-terminal Telopeptides of Type 1 Collagen) in Denosumab Clinical Studies
    Jin Wang
    Jean Lee
    Daniel Burns
    David Doherty
    Laura Brunner
    Mark Peterson
    Binodh DeSilva
    The AAPS Journal, 2009, 11 : 385 - 394
  • [9] The practicalities of a 'fit-for-purpose' validation
    Burton, Neil K.
    Wood, Stephen A.
    BIOANALYSIS, 2015, 7 (21) : 2735 - 2740
  • [10] Fit-for-purpose biomarker immunoassay qualification and validation: three case studies
    Cowan, Kyra
    Gao, Xiaoying
    Parab, Vaishali
    Trung Nguy
    Wu, Lawren
    Arron, Joseph R.
    Townsend, Michael
    Wallin, Jeffrey
    Cheu, Melissa
    Morimoto, Alyssa
    Wakshull, Eric
    BIOANALYSIS, 2016, 8 (22) : 2329 - 2340
12345